top of page

American Academy of Dermatology (AAD VMX) Virtual Meeting



Otezla presented a significant improvement in the disease severity in mild-to-moderate patients, according to the Phase 3 ADVANCE trial.

In the ADVANCE trial, Otezla 30 mg showed statistically significant improvement in the static Physician's Global Assessment (sPGA) response at week 16. 21.6% of patients reached the primary endpoint versus 4.1% in the placebo arm.

The drug has demonstrated improvement in all secondary endpoints. 29% of patients on Otezla showed at least 75% improvement in BSA versus 6.1% in the placebo arm.



BMS announced POETYK PSO-1 and POETYK PSO-2 trial results, demonstrating the superiority of deucravacitinib versus placebo and Otezla.

Deucravacitinib is an oral selective tyrosine kinase 2 (TYK2) inhibitor for treating patients with moderate-to-severe plaque psoriasis.

The primary endpoints were Psoriasis Area and Severity Index (PASI) 75 and a static Physician's Global Assessment score (sPGA 0/1) at week 16.

Results of POETYK PSO-1 trial

PASI 75 at week 16

  • Deucravacitinib 6 mg: 58.7%

  • Otezla: 35.1%

  • Placebo: 12.7%

PASI 75 at week 24

  • Deucravacitinib 6 mg: 69%

  • Otezla: 38.1%

Results of POETYK PSO-2 trial

PASI 75 at week 16

  • Deucravacitinib 6 mg: 53.6%

  • Otezla: 40.2%

  • Placebo: 9.4%

PASI 75 at week 24

  • Deucravacitinib 6 mg: 59.3%

  • Otezla: 37.8%



Eli Lilly presented BREEZE-AD5 Phase 3 clinical trial data and showed improvement of Olumiant versus placebo in moderate to severe atopic dermatitis patients.

Results of BREEZE-AD5 trial:

Eczema Area and Severity Index (EASI)

At week one

  • Olumiant: 25.3%

  • Placebo: 7.2%

At week 4

  • Olumiant: 50.9%

  • Placebo: 24%


Recent Posts

See All


bottom of page